Clinical efficacy of camrelizumab combined with apatinib versus camrelizumab combined with chemotherapy regimens as first-line treatment for advanced gastric cancer
- VernacularTitle:卡瑞利珠单抗联合阿帕替尼与其联合化疗方案一线治疗晚期胃癌的临床效果对比
- Author:
Ran JU
1
;
Qi MIAO
1
;
Jun YANG
1
;
Yonggui WANG
2
;
Xiangning DONG
3
Author Information
1. Dept. of Emergency Surgery，South Campus，Chuzhou Hospital Affiliated to Anhui Medical University （Chuzhou First People’s Hospital），Anhui Chuzhou 239000，China
2. Dept. of Emergency，South Campus，Chuzhou Hospital Affiliated to Anhui Medical University （Chuzhou First People’s Hospital），Anhui Chuzhou 239000，China
3. Dept. of Oncology，North Campus，Chuzhou Hospital Affiliated to Anhui Medical University （Chuzhou First People’s Hospital），Anhui Chuzhou 239000，China
- Publication Type:Journal Article
- Keywords:
camrelizumab;
apatinib;
advanced gastric cancer;
clinical efficacy;
immune function;
chemotherapy-related
- From:
China Pharmacy
2025;36(18):2307-2311
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To compare the clinical efficacy and safety of camrelizumab combined with apatinib versus camrelizumab combined with chemotherapy as first-line treatment for advanced gastric cancer. METHODS A prospective randomized controlled trial was conducted， enrolling 99 patients with advanced gastric cancer admitted to the Chuzhou First People’s Hospital from March 2022 to December 2024. Patients were randomly assigned using a random number table： 48 received camrelizumab plus chemotherapy （control group）， and 51 received camrelizumab plus apatinib （observation group）. Clinical efficacy， serum tumor marker[carcinoembryonic antigen（CEA），carbohydrate antigen（CA）724，CA199，CA242]levels， immune function indicators（CD3+，CD4+，CD8+，CD4+/CD8+） levels before and after treatment， and adverse drug reaction （ADR） during treatment were compared between the 2 groups. RESULTS A total of 2 patients in the observation group and 3 in the control group were lost to follow-up. The disease control rate and objective response rate in the observation group were 95.92% and 85.71%， respectively， both significantly higher than 80.00% and 55.56% in the control group （P＜0.05）. The median progression-free survival was 9.61 months in the observation group， significantly longer than 6.72 months in the control group （P＝0.011）. Before treatment， there was no statistically significant difference in the levels of serum tumor markers and immune function indicators between the 2 groups （P＞0.05）. After treatment， the levels of CEA， CA724， CA199 and CA242 in 2 groups were significantly lower than before treatment， while the levels of CD3⁺， CD4⁺ and CD4 ⁺/CD8 ⁺ were significantly higher than before treatment， with greater improvements in the observation group （all P＜0.05）. The overall incidences of ADR and severe ADR showed no statistically significant difference between the 2 groups （P＞0.05）. CONCLUSIONS Camrelizumab combined with apatinib as first-line therapy for advanced gastric cancer may offer advantages over camrelizumab plus chemotherapy in terms of clinical efficacy and immune function improvement of patients， with an acceptable safety profile.
